Jakoda Snider, MD
Family Medicine · Indianapolis, INNPI 1063894517
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $70,538 of the $106,913 with a category attached, or 66.0%. Gilead accounts for 99.7% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2024 at $31,117 and has fallen 51.6% since, to $15,057 in 2025. Among family medicine clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 131 payments — averaging $816.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$107K
- Viiv Healthcare Company$278
- Exact Sciences$13
What the payments were for
- Consulting fees$19,18018%
- Speaking & faculty fees$70,53866%
- Travel & lodging$12,93312%
- Food & beverage$4,2624%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 127 | $106,621 |
| Viiv Healthcare Company | 3 | $278 |
| Exact Sciences | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$106,913 in reported general payments places this provider in the 95th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 62 | $83,700 |
| MounjaroTirzepatide | 40 | $61,853 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $6,506 |
| VascepaIcosapent Ethyl | 12 | $4,048 |
| Pregabalin | 42 | $2,494 |
| Gabapentin | 103 | $2,043 |
| Clindamycin Phosphate | 19 | $1,236 |
| Lactulose | 20 | $1,116 |
| Atorvastatin Calcium | 90 | $1,056 |
| Bupropion XlBupropion Hcl | 39 | $778 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 63 | $777 |
| Duloxetine Hcl | 26 | $565 |
| Losartan Potassium | 46 | $528 |
| Omeprazole | 23 | $502 |
| Tamsulosin Hcl | 49 | $475 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Indianapolis
- Richard TannerIndianapolis$1.6M
- Richard FeldmanIndianapolis$476K
- Joe BanksIndianapolis$294K
- Robert ClutterIndianapolis$77K
- Blair BrengleIndianapolis$17K
- James AndryBloomington$715K
- Anthony InzerelloEvansville$308K
- Steven GatewoodElwood$281K
- Shekar PushpalaCarmel$239K
- Victoria MoyerKokomo$188K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.